Drug Type Monoclonal antibody |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Xenothera SASStartup |
Active Organization Xenothera SASStartup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasm Metastasis | Phase 2 | BE | Xenothera SASStartup | 14 Nov 2023 |
Neoplasm Metastasis | Phase 2 | FR | Xenothera SASStartup | 14 Nov 2023 |
Solid tumor | Phase 2 | FR | Xenothera SASStartup | 14 Nov 2023 |
Solid tumor | Phase 2 | BE | Xenothera SASStartup | 14 Nov 2023 |
Hematologic Neoplasms | Phase 1 | FR | Xenothera SASStartup | - |